Rezolute (RZLT) has released an update to notify the public and investors about a regulation fd disclosure.
The U.K. Medicines and Healthcare products Regulatory Agency awarded the Innovation Passport to RZ358 for treating congenital hyperinsulinism-related hypoglycemia, as announced by the Company on January 23, 2024. The following day, the Company announced Mr. Evans as the new Chief Financial Officer. The disclosures in this context are not considered legally “filed” under the Securities Exchange Act of 1934, nor are they liable under Section 18, and they’re not included in any filings under the Securities Act of 1933 unless explicitly referenced.
For further insights into RZLT stock, check out TipRanks’ Stock Analysis page.
